Novogene's Chinese clinical lab will offer LifeMap's recently updated TGex next-generation sequencing data analysis and interpretation platform.
The firm's next-generation sequencing diagnostic test analyzes tumor samples from multiple genomic mutations that are targeted by therapies for non-small cell lung cancer.
The partners will develop next-generation sequencing-based tests for precision cancer treatment for the Asian market.
Researchers identified trait-related variants by sequencing more than 400 upland cotton accessions and nearly 250 representatives from two diploid Gossypium species.
The lab is located within Novogene's sequencing center at the Sacramento campus of the University of California, Davis.
The Chinese government has implemented clearer regulatory guidance for genomic tests and invested in both clinical testing and research, spurring growth.
The firms plan to focus on sample processing methods, workflow automation, algorithms, and database construction.
Novogene will validate Trovagene's proprietary urine collection and nucleic acid preservation device, NextCollect, and develop tests for the Chinese market.
The Genome Institute of Singapore will collaborate with the new center to develop applications related to cancer diagnosis and treatment stratification.
The genomic sequencing firm will use the financing to support growth in both the research and clinical NGS market.
An artificial intelligence-based analysis suggests a third group of ancient hominins likely interbred with human ancestors, according to Popular Mechanics.
In Science this week: reduction in bee phylogenetic diversity, and more.
The New York Times Magazine looks into paleogenomics and how it is revising what's know about human history, but also possibly ignoring lessons learned by archaeologists.
The Economist reports on Synthorx's efforts to use expanded DNA bases they generated to develop a new cancer drug.